Zheng Zehao, Guan Renguo, Jianxi Wang, Zhao Zhen, Peng Tianyi, Liu Chunsheng, Lin Ye, Jian Zhixiang
Shantou University Medical College, Shantou, China.
Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
J Oncol. 2022 Mar 30;2022:9567041. doi: 10.1155/2022/9567041. eCollection 2022.
Hepatocellular carcinoma (HCC) is one of the most common types of malignancies in the world, and most HCC patients undergoing liver resection relapse within five years. Microvascular invasion (MVI) is an independent factor for both the disease-free survival and overall survival of HCC patients. At present, the definition of MVI is still controversial, and a global consensus on how to evaluate MVI precisely is needed. Moreover, this review summarizes the current knowledge and clinical significance of MVI for HCC patients. In terms of management, antiviral therapy, wide surgical margins, and postoperative transcatheter arterial chemoembolization (TACE) could effectively reduce the incidence of MVI or improve the disease-free survival and overall survival of HCC patients with MVI. However, other perioperative management practices, such as anatomical resection, radiotherapy, targeted therapy and immune therapy, should be clarified in future investigations.
肝细胞癌(HCC)是全球最常见的恶性肿瘤类型之一,大多数接受肝切除的HCC患者会在五年内复发。微血管侵犯(MVI)是影响HCC患者无病生存期和总生存期的独立因素。目前,MVI的定义仍存在争议,需要就如何精确评估MVI达成全球共识。此外,本综述总结了MVI对HCC患者的现有认识及临床意义。在治疗方面,抗病毒治疗、宽手术切缘以及术后经动脉化疗栓塞(TACE)可有效降低MVI的发生率,或改善伴有MVI的HCC患者的无病生存期和总生存期。然而,其他围手术期管理措施,如解剖性切除、放疗、靶向治疗和免疫治疗,应在未来的研究中予以明确。